Results support advancement into phase 2 trials

Agreement enables procurement in over 50 countries

Results support combination strategy for influenza vaccines

Global trials assess migraine prevention potential

Recommendation supports second-line combination option

Positive opinion supports EU marketing authorisation

Regimen update recommended across all indications

New Frankfurt site to boost long-term supply

New company to advance first‑in‑class treatment

Phase 2 development underway as DARE2 trial begins